Last reviewed · How we verify
HighT
HighT, developed by the University of Colorado, Denver, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its current market presence and patent protection. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | HighT |
|---|---|
| Also known as | Androgel |
| Sponsor | University of Colorado, Denver |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer (PHASE2)
- Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (PHASE3)
- Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (PHASE2)
- Effect of Liposome Bupivacaine Serratus Plane Block on Postoperative Hyperalgesia and Chronic Post-surgical Pain in Patients Undergoing Radical Mastectomy (PHASE1, PHASE2)
- Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis
- Precision of Pacient-specific Instrumented Open Wedge High Tibial Osteotomy vs Conventional Technicque (NA)
- The Effect of Eight Weeks of High-Intensity Interval Training on Physical Performance in Young Taekwondo Athletes (NA)
- Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |